Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cures Excitement May Wane While Senate Works

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Health Committee continues work on its own 21st Century Cures-related legislation, meaning the newly passed House bill will be out of the spotlight for a bit.


Related Content

US FDA Getting More Money Up Front Under Cures Bill Revisions
Senators Circulate Plan For Stand-alone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules
FDA Central Review Likely For Novel Surrogate Endpoints
Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining